Immunosuppression and Transplantation


Published on

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Immunosuppression and Transplantation

  1. 1. Immunosuppression and Transplantation Yufang Shi, D.V.M, Ph.D. E-mail: [email_address]
  2. 2. Transplantation in Clinic Body parts: Facial, Limbs, Organs: Heart, kidney , liver Tissue: Islets, hair follicles, bone, bone marrow Cells: Stem cells, lymphocytes
  3. 3. <ul><li>Most surgical procedures are well established </li></ul><ul><li>**Immunosuppression </li></ul><ul><li>Organ variation: liver is easier to tolerize </li></ul><ul><li>Cornea very little rejection </li></ul><ul><li>Skin is most difficult </li></ul>Transplantation Hurdles
  4. 4. The dream of transplants The 3 rd Century, Saints Cosmas and Damian
  5. 6. Relationships between Donor and Recipient Syngeneic - between genetically identical individuals, usually the same individual, identical twins or isogenic strains Allogeneic - from one individual to another of the same species Xenogeneic - between individuals of different species.
  6. 7. Immunological Rej e ction <ul><li>Major Histocompatibility Complex (MHC) is the major concern. </li></ul><ul><li>Rejections: </li></ul><ul><li>Antibody mediated </li></ul><ul><li>T cells mediated </li></ul><ul><li>Hyperacute rejection </li></ul><ul><li>e.g., Blood type mismatch </li></ul><ul><li>Acute Graft Rejection </li></ul><ul><li>Direct recognition of allogeinic MHC; re j ection about 10 days </li></ul><ul><li>Chronic rejection </li></ul><ul><li>Take many months to years. Due to failure of immunosuppressant s </li></ul>
  7. 8. 1906 The first kidney transplantations were done without anti-rejection drugs. Kidneys from sheep, pigs, goats and primates are used. 1936 Dr. Voronoy, a Russian, reports the first human-to-human kidney transplant , when a kidney from a cadaver is transplanted to a recipient with a different blood type. ** 1944 A British scientist, Sir Peter Medawar, reports that rejection of a transplant is based on immunologic factors . This discovery eventually transforms transplant surgery from a largely unsuccessful experiment to an accepted form of treatment. 1954 Surgeons Joseph E. Murray and John Hartwell Harrison, in collaboration with nephrologist John P. Merrill, perform the first successful kidney transplant -- between identical twins -- at the Peter Bent Brigham Hospital in Boston. 1963 Dr. Thomas E. Starzl performs the first human liver transplant at the University of Colorado Medical School; however, lack of effective immunosuppressives limits the success. Four years later, the availability of more effective immunosuppressives enables Dr. Starzl to perform the first successful liver transplant. 1963 Dr. James D. Hardy performs the first lung transplant at the University of Mississippi at Jackson; however, the patient survives only a few days because of the lack of effective immunosuppression drugs. Twenty years later, with improved immunosuppressives, Dr. Joel Cooper performs the first successful lung transplant at Toronto General Hospital. 1967 Dr. Christiaan Barnard performs the first heart transplant at Groote Shuur in Cape Town, South Africa. Milestones In Organ Transplantation (1) Source: National Kidney Foundation, Inc.
  8. 9. Milestones In Organ Transplantation (2) Source: National Kidney Foundation, Inc. 1968 Dr. Norman Shumway performs the first U.S. heart transplant at Stanford University. 1968 Drs. Richard Lillehei and William Kelly perform the first pancreas transplant at the University of Minnesota Hospital. ** 1979 U.S. trials of Sandimmune (cyclosporine ) in cadaver kidney transplants begin at the Peter Bent Brigham Hospital in Boston and at the University of Colorado. The results show that Sandimmune (cyclosporine), combined with steroids, controls rejection better than any drug therapy in the past. 1983 The Federal Drug Administration releases Sandimmune (cyclosporine) for general use in the U.S., heralding a new era for kidney, liver and heart transplantation. 1986 Dr. A. Benedict Cosimi and his associates at Massachusetts General Hospital introduce monoclonal antibodies into clinical medicine in the form of OKT3 antibodies, which have a selective effect on the immune system and are intended primarily for reversing kidney transplant rejection. 1989 Clinical investigators begin using an experimental drug called FK 506 for kidney, liver, heart and lung recipients. Results suggest that this drug is effective, but clinical trials continue to assess its safety and efficacy. 1993 Continuing shortages in organ donation lead to renewed interest in transplanting organs from animals such as baboons (often referred to as xenografting). Baboon-to-human liver and heart transplants have been attempted, with limited success. A new research strategy involves developing a line of pigs with the appropriate human genes to help prevent rejection of organs such as hearts, livers and kidneys transplanted from these animals.
  9. 10. 1994 The FDA approve s a new medication for use in transplant recipients: Prograf (formerly known as FK506 ) marks a significant advance in the understanding and suppression of the human rejection response and in the lessening of unwanted side effects. 1995 A new study by Dr. Paul Terasaki and colleagues at UCLA shows that spouses are an important source of living-donor kidney transplants. According to the Terasaki study, the 3-year graft survival rate for spouse-to-spouse transplants (85%) is comparable to that seen in parent-to-child transplants (82%) and better than that seen in transplants from cadaver donors (70%). Living donation is becoming an increasingly important source of kidney and other transplants because of continuing shortages of cadaver donors. 1995 Two more new medicines are approved by the FDA for use in transplant recipients. These are: CellCept (mycophenolate mofetil), and Neoral, a new formulation of cyclosporine. These drugs hold promise for providing even better control of rejection with fewer side effects. 1995 At Johns Hopkins Bayview Medical Center, Lloyd Ratner, M.D. and Louis Kavoussi, M.D., perform the world's first laparoscopic live-donor nephrectomy in which a patient's kidney is removed through a hole slightly larger than a silver dollar. Laparoscopic live-donor nephrectomies mean fewer post-op days in the hospital, speedier recovery, less scarring and decreased post-operative pain. 1996 The number of kidney transplants using living donors (both related and unrelated) continues to grow. A total of 11,099 kidney transplants were performed in 1996 -- 3,389 of which involved kidneys recovered from living donors. 1997 The Department of the Navy Bureau of Medicine and Surgery announces a research breakthrough that they are now able to prevent kidney transplant rejection in primates with different histocompatibility factors through the use of a combination of a specific fusion protein and a specific monoclonal antibody . Further trials are necessary to determine future applicability of the technique to humans. Milestones In Organ Transplantation (3) Source: National Kidney Foundation, Inc.
  10. 11. Anti-inflammatory and Immunosuppressive Drugs Nonsteroid anti-inflammatory drugs: Aspirin, Vioxxx (no longer used), and Celebrex. Work through COX1/2 (cylooxygeneases, which are involved in the synthesis of prostaglandins) Antihistamines: Blockers of histamine receptors: Allegra, Claritin, Clarinex, Benadryl * Steroid hormones: Glucocorticoid derivatives: prednisone, dexamethasone, and hydrocortisone * Lymphocyte specific immunosuppressants : Cyclosoprine, FK506, rapamycin, FTY720, specific antibodies and receptors (bioactive). Cytotoxic agents: cyclophosphamide
  11. 12. Simplified Schematic Representation of an Immune Response Class I MHC class II/peptides APCs Protein antigens CD8 + T cells CD4 + T cells B cells Plasma cells CD8 + cytolytic T cells CD4 + immune cells (delayed hypersensitivity) antibody production proliferation & differentiation IFN  , IL-2 Cytokines Costim. Mol . IL-4,-5,-6 proliferation & differentiation APC Class II proliferation & differentiation
  12. 13. © 2003 by LIPPINCOTT WILLIAMS & WILKINS Fundamental Immunology TCR Costimulation
  13. 14. Families of Costimulation Molecules B7:CD28 superfamily: B7.1/B7.2:CD28/CTLA4; ICOSL:ICOS; PD-L1/PD-L2:PD-1; B7-H3:? TNF:TNFR superfamily: CD134 (OX40):CD134L; CD27:CD70; 4-1BB:4-1BBL; CD30:CD30L; RANK (OPG):RANKL; LIGHT:HVEM, and GITR:GITRL CD2 superfamily: CD2:CD58/CD48; CD48:CD244 CD150, CD84, CD299, Ly-108, and BLAM Some integrins: CD44, CD43, and heat-stable antigen (HSA).
  14. 15. TCR Activation
  15. 16. T-cell Activation Blockers: Cyclosporine, Tacrolimus (FK506), and Sirolimus (Rapamycin) <ul><li>CsA and FK506 act on T-cells to inhibit T-cell receptor activation and induction of cytokines </li></ul><ul><li>CsA may also inhibit IgE-stimulated mast cell degranulation and stimulate TGF-  expression </li></ul><ul><li>Rapamycin acts to inhibit lymphocyte response to cytokines </li></ul><ul><li>Rapamycin and analogues are also used to sensitize cancer cells to chemotherapeutic reagents </li></ul>
  16. 17. FKBP Rapamycin mTor FK506 Cyclosporine Cyclophilin Calcineurin Cytokine Signaling NFAT Translocation Genes lead to T cell Activation Targets of Immunosuppressants
  17. 18. Target of Rapamycin
  18. 19. Mechanism of Action of Helper T-cell blockers X X From Hardman and Limbird, The Pharmacological Basis of Therapeutics
  19. 20. Cyclophilin is a peptidyl-prolyl cis-trans-isomerase which catalyzes the cis-trans isomerization of proline imidic peptide bonds. Helps protein folding. FKBPs are also known to participate in many cellular processes such as cell signaling, protein transport (such as Notch) and transcription. Immunophilins
  20. 21. Newton, Thorax 2000; 55: 603-613 Biology of Glucocorticoids
  21. 22. Newton, Thorax 2000; 55: 603-613 Mechanisms of Glucocorticoid Action <ul><li>Inhibit the production of </li></ul><ul><li>proinflammatory cytokines </li></ul><ul><li>Promote the production of </li></ul><ul><li>inflammatory cytokines </li></ul><ul><li>Induce apoptosis in </li></ul><ul><li>inflammatory cells </li></ul><ul><li>4. Interfere with cytokine signals </li></ul>
  22. 23. Glucocorticoid-sensitive sites of the immune response MHC Class I/peptides APCs MHC Class II/peptides APCs Protein antigen CD8 T-cell CD4 T-cell (helper T-cells) B-cell Plasma cell CD8 cytolytic T-cells CD4 immune cell (delayed hypersensitivity) antibody production proliferation & differentiation proliferation IL-2 IL-1 IL-1, -4,-5,-6 proliferation & differentiation GC X X GC X X
  23. 24. Use of Glucocorticoid as Immunosuppressants <ul><li>Most widely used effective anti-inflammatory drugs </li></ul><ul><li>Used with other immunophilin inhibitors to prevent transplant rejection and GVHD </li></ul><ul><ul><li>natural glucocorticoids not used due to mineralocorticoid activity </li></ul></ul><ul><li>P rednisone and prednisolone are used orally at moderate to high doses; Very high doses of methylprednisolone used i.v. during acute organ rejection </li></ul><ul><li>Used before and after anti-thymocyte Abs to inhibit allergic reactions </li></ul>
  24. 25. General Principles of Immunosuppression <ul><li>Primary immune responses are more easily suppressed than secondary (memory) </li></ul><ul><li>Different immunosuppressants have different effects on different immune reactions </li></ul><ul><li>Suppression is more likely achieved if therapy begins before exposure to the immunogen </li></ul>
  25. 26. Uses of Calcineurin inhibitors (TCR activation blockers) <ul><li>Cyclosporine commonly used with prednisone and other immunosuppressants to prevent allograft rejections in renal, hepatic and cardiac transplants, and in RA and psoriasis </li></ul><ul><ul><li>use is delayed posttransplantation due to neurotoxicity concerns </li></ul></ul><ul><li>FK506 (Tacrolimus) is approved for prevention of solid-organ allograft rejection, and eczema (topical) </li></ul><ul><ul><li>Treatment begins prior to surgery, and is maintained well afterwards </li></ul></ul>
  26. 27. Glucocorticoid effects related to immunosuppression <ul><li>Reduced immune cell content of lymph nodes, spleen and blood </li></ul><ul><ul><li>lymphopenia, monocytopenia, eosinopenia, but neutrophilia </li></ul></ul><ul><li>Interference with APC, T-cell and macrophage functions </li></ul>
  27. 28. Sirolimus (Rapamycin, Rapamune): a new T-cell blocker <ul><li>different mechanism of action </li></ul><ul><ul><li>blocks mTOR kinase </li></ul></ul><ul><li>similar poor bioavailability as cyclosporine and tacrolimus, much longer half-life; 62 h v. 18 and 12 h </li></ul><ul><li>same metabolism (CYP3A) and potential drug interactions </li></ul><ul><li>used for prophylaxis of organ transplant rejection in combination with a calcineurin inhibitor and glucocorticoids </li></ul><ul><li>toxicities include: </li></ul><ul><ul><li>hyperlipidemia, lymphocoele, anemia, leukopenia, thrombocytopenia, fever, GI effects, hyper- or hypokalemia </li></ul></ul>
  28. 29. Toxicity of Glucocorticoids <ul><li>Major side effects are common due to high doses necessary for suppression </li></ul><ul><ul><li>Cushings syndrome </li></ul></ul><ul><ul><li>glucose intolerance </li></ul></ul><ul><ul><li>infections </li></ul></ul><ul><ul><li>bone dissolution </li></ul></ul><ul><ul><li>muscle wasting </li></ul></ul>
  29. 30. Cytotoxic Agents as immunosuppressants <ul><li>Antineoplastic drugs will also prevent clonal expansion of T- and B-cells </li></ul><ul><ul><li>azathioprine (prodrug of nucleotide anti-metabolite) </li></ul></ul><ul><ul><li>mycophenolate mofetil </li></ul></ul><ul><ul><ul><li>becomes MPA; inhibits IMP dehydrogenase </li></ul></ul></ul><ul><ul><li>cyclophosphamide (DNA alkylating agent) </li></ul></ul><ul><ul><li>methotrexate (inhibits dihydrofolate reductase) </li></ul></ul>
  30. 31. Uses of cytotoxic agents <ul><li>Azathioprine; with cyclosporine and/or prednisone for organ transplant rejection and severe RA </li></ul><ul><li>Mycophenolate mofetil; with cyclosporine and prednisone for renal transplants </li></ul><ul><li>Cyclophosphamide; for BMT </li></ul><ul><li>Methotrexate; GVHD prophylaxis </li></ul>
  31. 32. Bioactive Immunosuppressants <ul><li>Anti-thymocyte antibodies </li></ul><ul><ul><li>3 types available </li></ul></ul><ul><ul><ul><li>all derived from non-human sources </li></ul></ul></ul><ul><li>Rh(D) immune globulin </li></ul><ul><li>OKT3, OKT4, Anti-CD20, anti-TNF, anti-ICAMs, and CTLA4-Ig </li></ul><ul><li>Repeated blood transfusion; transfusion of apoptotic cells </li></ul>
  32. 33. History of Immunosuppressants (1) Significant Prolongation of canine Kidney Graft Survival Azathioprin( Aza) Calne,Zckoski 1960 Prolongation of Cadaveric Kidney Graft Survival TLI+Autogeneic BMT Hamburger 1959 Inhibition of Antibody Production, Prolongation of Skin Graft Survival 6-MP Schwartz,Dameshek 1959 Prolongation of Mouse Skin Graft Survival X-irradiation+BMT Loutit 1952 Prolongation of canine Kidney Graft Survival cortisteroid+Splenectomy Baker 1952 Recipient Died of Systemic Infection Cadaveric Kidney Tx+ TLC Hume 1950 Prolongation of Skin Graft of Rabbit and Mice Corticosteroids Billingham 1950 Result Experiment or Clinical application author Time Became a Clinical Routine Aza+Corticosteroid Starzl 1963 Prolongation of Cadaveric Kidney Graft Survival TLI+6-MP Kuss 1960
  33. 34. History of Immunosuppressants (2) Results Experiment or Clinical Application Author Time Strong Immunosuppresion and Less Infection The Finding of CsA Borel 1976 Enhanced Survival Rate of Cadaveric Kidney Graft by 20% Prooperative Blood Transfusion Opelz 1973 To Replace Aza When Severely Toxic CHX Starzl 1970 No Obvious Effect Irradiation of Cadaveric Kidney Wolf 1969 Clinical Use of ALS, Still in Use Clinically ALS Starzl 1967 Prolongation of Graft Survival of Mouse Skin and Canine Kidney ALS Russell Monaco 1967 Transient Effect , Technical Difficulty Thoracic Duct Drainage McGregor,Gowans 1964 Not so Good, Seldom Used Preoperative Splenectomy Srarzl 1963
  34. 35. Currently Used Immunosuppressants Chinese Medicine CsA FK506 Rapamicin , Cellcept ( mycophenolate mofetil ) Fungus Products ALG (anti-lymphocyte globulins), ATG (anti-thymocyte globulins), OKT3 Biological Agents Predenisone,Prednisolone, Dexamethasone, etc Steroids Azathioprin ( Aza) Antimetabolic Agent Cyclophosphamide Alkyl Agent Drugs Category
  35. 36. Ideal Immunosuppressant <ul><li>Strongly Immunosuppressive </li></ul><ul><li>Specific, No Overall Immunosuppression </li></ul><ul><li>Anti-infection ability </li></ul><ul><li>Low Toxicity for Vital Organs </li></ul><ul><li>Low cost </li></ul><ul><li>Long in vivo bioactivity </li></ul><ul><li>Easy to use </li></ul>
  36. 37. Clinical Tolerance Established <ul><li>Absence of Pathogenic Immune Response Against Graft Tissue </li></ul><ul><li>With little or no Immune Suppressant </li></ul><ul><li>With the Retention of Immune Responses Against Other Infectious Antigens </li></ul>
  37. 38. Help on the Way Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo. Lancet. 2004 May 1;363:1439-41.